13F Filings History of Venrock Adviser, LLC
- Latest 13F filing
- Q1 2026 - 15 May 2026
- Latest reported 13F value
- $2,679,121,858
- Largest 13F holdings
-
APGE ERAS ORKA SYRE KALV DNTH DMRA OCUL COGT VRDN SVRA ELVN
+8 more
ORIC VOR MAZE CTMX JBIO DYN CBIO ZURA - Form 13F summary
-
- Venrock Adviser, LLC Form 13F history summarizes parsed U.S.-listed equity disclosures for this manager.
- Form 13F is generally due within 45 days after each calendar quarter ends.
- Venrock Adviser, LLC reported 33 equity holdings with a total reported market value of $2,679,121,858 for Q1 2026. Top reported holdings included APGE, ERAS, ORKA, SYRE, and KALV.
- Manager signature
- Sherman G. Souther - Authorized Signatory
- Manager location
- New York, NY
13F snapshot
Latest parsed holdings, value, and filing-period context.
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow Venrock Adviser, LLC with Pro and return when a new 13F portfolio filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
Holdings Value
Form 13F evidence
Quarterly portfolio filings
SEC-reported 13F quarters for this filer, ordered by the latest accepted filing.
Latest quarter
Q1 2026
Latest value
$2,679,121,858
Quarter delta
+$654,604,026
Accepted
15 May 2026, 16:04
Rows shown
1-25 of 25
| Quarter | Holdings | SEC-reported value | Bought | Sold | Net | Top Holdings | Form Type | Accepted by SEC |
|---|---|---|---|---|---|---|---|---|
| Q1 2026 | 33 | $2,679,121,858 | +$288,251,643 | -$166,289,071 | +$121,962,572 | APGE, ERAS, ORKA, SYRE, KALV | 13F-HR | 15 May 2026, 16:04 |
| Q4 2025 | 27 | $2,024,517,832 | +$116,812,658 | -$533,926,165 | -$417,113,507 | APGE, ORKA, VRDN, SYRE, KALV | 13F-HR | 17 Feb 2026, 16:57 |
| Q3 2025 | 33 | $1,776,690,536 | +$112,937,875 | -$149,495,863 | -$36,557,988 | APGE, MTSR, OCUL, CDTX, VRDN | 13F-HR | 14 Nov 2025, 16:31 |
| Q2 2025 | 31 | $1,334,436,576 | +$141,846,744 | -$120,383,217 | +$21,463,527 | APGE, OCUL, MTSR, ELVN, KALV | 13F-HR | 14 Aug 2025, 16:48 |
| Q1 2025 | 37 | $1,175,247,364 | +$151,798,360 | -$70,868,186 | +$80,930,174 | APGE, MTSR, OCUL, ELVN, KALV | 13F-HR | 15 May 2025, 16:07 |
| Q4 2024 | 37 | $1,457,403,476 | +$94,777,575 | -$134,402,512 | -$39,624,937 | APGE, OCUL, ELVN, PRAX, VRDN | 13F-HR | 14 Feb 2025, 16:16 |
| Q3 2024 | 38 | $1,909,252,051 | +$116,126,312 | -$74,647,649 | +$41,478,663 | APGE, OCUL, ELVN, VRDN, APLT | 13F-HR | 14 Nov 2024, 16:16 |
| Q2 2024 | 35 | $1,570,242,514 | +$121,348,192 | -$156,573,166 | -$35,224,974 | APGE, ELVN, FDMT, OCUL, DYN | 13F-HR | 14 Aug 2024, 16:15 |
| Q1 2024 | 38 | $2,102,200,301 | +$422,632,491 | -$404,131,482 | +$18,501,009 | APGE, FDMT, OCUL, SYRE, MRUS | 13F-HR | 15 May 2024, 16:17 |
| Q4 2023 | 36 | $1,458,067,955 | +$331,373,848 | -$144,656,305 | +$186,717,543 | RYZB, APGE, PHVS, VRDN, FDMT | 13F-HR | 14 Feb 2024, 16:15 |
| Q3 2023 | 37 | $949,945,221 | +$430,560,447 | -$96,044,917 | +$334,515,530 | APGE, RYZB, VRDN, COGT, TSHA | 13F-HR | 14 Nov 2023, 16:17 |
| Q2 2023 | 30 | $625,361,199 | +$181,088,605 | -$114,390,928 | +$66,697,677 | VRDN, COGT, FDMT, ELVN, MRUS | 13F-HR | 11 Aug 2023, 16:16 |
| Q1 2023 | 25 | $512,168,605 | +$109,779,144 | -$132,749,927 | -$22,970,783 | VRDN, COGT, ELVN, TERN, PLRX | 13F-HR | 15 May 2023, 16:16 |
| Q4 2022 | 28 | $593,604,538 | +$195,835,701 | -$157,563,508 | +$38,272,193 | VRDN, ACRS, AXSM, COGT, TERN | Restatement | 15 May 2023, 16:16 |
| Q3 2022 | 31 | $553,340,845 | +$152,747,143 | -$142,811,648 | +$9,935,495 | ACRS, COGT, RLMD, VRDN, GHRS | Restatement | 15 May 2023, 16:15 |
| Q2 2022 | 27 | $438,807,039 | +$101,712,014 | -$91,332,685 | +$10,379,329 | ACRS, RLMD, TVTX, COGT, GHRS | Restatement | 15 May 2023, 16:15 |
| Q1 2022 | 27 | $617,244,000 | +$46,826,057 | -$41,902,569 | +$4,923,488 | ACRS, TIL, RLMD, TVTX, GHRS | 13F-HR | 16 May 2022, 16:05 |
| Q4 2021 | 26 | $731,539,000 | +$167,597,689 | -$107,082,025 | +$60,515,664 | TIL, ACRS, TVTX, RLMD, GHRS | 13F-HR | 14 Feb 2022, 16:06 |
| Q3 2021 | 26 | $764,338,000 | +$139,703,207 | -$146,244,000 | -$6,540,793 | TIL, ACRS, CLDX, AADI, VTGN | 13F-HR | 15 Nov 2021, 16:08 |
| Q2 2021 | 29 | $824,402,000 | +$210,532,546 | -$180,311,735 | +$30,220,811 | TIL, ACRS, VTGN, GRPH, MRNS | 13F-HR | 13 Aug 2021, 16:05 |
| Q1 2021 | 28 | $921,764,000 | +$370,502,157 | -$77,513,356 | +$292,988,801 | TIL, CNST, ACRS, OLMA, ALT | 13F-HR | 14 May 2021, 16:05 |
| Q4 2020 | 25 | $680,145,000 | +$258,684,426 | -$176,037,249 | +$82,647,177 | CNST, OLMA, TRILLIUM THERAPEUTICS INC, KNTE, ATHA | 13F-HR | 12 Feb 2021, 16:06 |
| Q3 2020 | 22 | $511,173,000 | +$153,888,137 | -$138,297,216 | +$15,590,921 | TRILLIUM THERAPEUTICS INC, CNST, ALT, ATHA, SURF | 13F-HR | 16 Nov 2020, 16:01 |
| Q2 2020 | 16 | $417,632,000 | +$178,602,000 | -$160,591,931 | +$18,010,069 | CNST, TRILLIUM THERAPEUTICS INC, ALT, RLMD, SURF | 13F-HR | 14 Aug 2020, 16:27 |
| Q1 2020 | 16 | $369,181,000 | $0 | $0 | $0 | CNST, AXSM, RLMD, TRILLIUM THERAPEUTICS INC, ETNB | 13F-HR | 15 May 2020, 16:05 |